Our finding that EHMT2 is overexpressed in breast cancer cells suggests that the development of a novel EHMT2 inhibitor may provide a mechanism for activating an autophagy initiating gene, Beclin-1, in cancer cells. The gene discussed is BECN1; the disease is cancer.